98 related articles for article (PubMed ID: 28972876)
21. CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells.
Xie B; Zhao L; Zhang Z; Zhou C; Tian Y; Kang Y; Chen J; Wei H; Li L
BMC Cancer; 2023 Oct; 23(1):955. PubMed ID: 37814227
[TBL] [Abstract][Full Text] [Related]
22. Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.
Ma J; Zeng F; Ma C; Pang H; Fang B; Lian C; Yin B; Zhang X; Wang Z; Xia J
Am J Cancer Res; 2016; 6(6):1384-95. PubMed ID: 27429851
[TBL] [Abstract][Full Text] [Related]
23. DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.
Kang X; Li M; Zhu H; Lu X; Miao J; Du S; Xia X; Guan W
Oncotarget; 2017 Nov; 8(55):94028-94039. PubMed ID: 29212207
[TBL] [Abstract][Full Text] [Related]
24. RHOJ controls EMT-associated resistance to chemotherapy.
Debaugnies M; Rodríguez-Acebes S; Blondeau J; Parent MA; Zocco M; Song Y; de Maertelaer V; Moers V; Latil M; Dubois C; Coulonval K; Impens F; Van Haver D; Dufour S; Uemura A; Sotiropoulou PA; Méndez J; Blanpain C
Nature; 2023 Apr; 616(7955):168-175. PubMed ID: 36949199
[TBL] [Abstract][Full Text] [Related]
25. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
Geretto M; Pulliero A; Rosano C; Zhabayeva D; Bersimbaev R; Izzotti A
Am J Cancer Res; 2017; 7(6):1350-1371. PubMed ID: 28670496
[TBL] [Abstract][Full Text] [Related]
26. LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
Yang L; Wang M; Wang Y; Zhu Y; Wang J; Wu M; Guo Q; Han X; Pandey V; Wu Z; Lobie PE; Zhu T
Oncogene; 2024 Apr; 43(17):1249-1262. PubMed ID: 38418543
[TBL] [Abstract][Full Text] [Related]
27. Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer.
Nwaeburu CC; Abukiwan A; Zhao Z; Herr I
Mol Cancer; 2023 Aug; 22(1):123. PubMed ID: 37542316
[No Abstract] [Full Text] [Related]
28. A PTAL-miR-101-FN1 Axis Promotes EMT and Invasion-Metastasis in Serous Ovarian Cancer.
Liang H; Yu M; Yang R; Zhang L; Zhang L; Zhu D; Luo H; Hong Y; Yu T; Sun J; Shan H; Gu Y
Mol Ther Oncolytics; 2020 Mar; 16():53-62. PubMed ID: 31930166
[TBL] [Abstract][Full Text] [Related]
29. Theacrine attenuates epithelial mesenchymal transition in human breast cancer MDA-MB-231 cells.
Ko JH; Yang MH; Baek SH; Nam D; Jung SH; Ahn KS
Phytother Res; 2019 Jul; 33(7):1934-1942. PubMed ID: 31172618
[TBL] [Abstract][Full Text] [Related]
30. Identification of the hub genes RUNX2 and FN1 in gastric cancer.
Han C; Jin L; Ma X; Hao Q; Lin H; Zhang Z
Open Med (Wars); 2020; 15(1):403-412. PubMed ID: 33313404
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion.
Cai X; Liu C; Zhang TN; Zhu YW; Dong X; Xue P
J Cell Biochem; 2018 Jun; 119(6):4717-4728. PubMed ID: 29274284
[TBL] [Abstract][Full Text] [Related]
32. miRNAs as short non-coding RNAs in regulating doxorubicin resistance.
Mirzaei S; Paskeh MDA; Moghadam FA; Entezari M; Koohpar ZK; Hejazi ES; Rezaei S; Kakavand A; Aboutalebi M; Zandieh MA; Rajabi R; Salimimoghadam S; Taheriazam A; Hashemi M; Samarghandian S
J Cell Commun Signal; 2023 Dec; 17(4):1181-1202. PubMed ID: 38019354
[TBL] [Abstract][Full Text] [Related]
33. Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.
Sadeghi MS; Lotfi M; Soltani N; Farmani E; Fernandez JHO; Akhlaghitehrani S; Mohammed SH; Yasamineh S; Kalajahi HG; Gholizadeh O
Cancer Cell Int; 2023 Nov; 23(1):284. PubMed ID: 37986065
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs in T Cell-Immunotherapy.
Dosil SG; Rodríguez-Galán A; Sánchez-Madrid F; Fernández-Messina L
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613706
[TBL] [Abstract][Full Text] [Related]
35. microRNA Expression Profile of Purified Alveolar Epithelial Type II Cells.
Dehmel S; Weiss KJ; El-Merhie N; Callegari J; Konrad B; Mutze K; Eickelberg O; Königshoff M; Krauss-Etschmann S
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011331
[TBL] [Abstract][Full Text] [Related]
36. Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.
Jo H; Shim K; Jeoung D
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682560
[TBL] [Abstract][Full Text] [Related]
37. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
Alam MS; Sultana A; Reza MS; Amanullah M; Kabir SR; Mollah MNH
PLoS One; 2022; 17(5):e0268967. PubMed ID: 35617355
[TBL] [Abstract][Full Text] [Related]
38. Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.
Pandit A; Begum Y; Saha P; Srivastava AK; Swarnakar S
Front Oncol; 2021; 11():720622. PubMed ID: 35145899
[TBL] [Abstract][Full Text] [Related]
39. The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
Xu D; Zhang Y; Jin F
BMC Cancer; 2021 Dec; 21(1):1321. PubMed ID: 34886806
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer.
Zhang S; Xiang X; Liu L; Yang H; Cen D; Tang G
Cancer Manag Res; 2021; 13():8929-8951. PubMed ID: 34876855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
